Background: Active stents seems to improve the outcome after percutaneous intervention (PCI) in reducing MACE at 9 months. However no prospective data comparing various devices are available. Method: Since March 2003, all patients suitable for stent implantation were randomized to receive either a sirolimus eluting stent (SES) or a paclitaxel active stent (PAS). Standard procedures were performed. Aspirin and clopidogrel were initiated for at least one year. Clinical outcome (MACE incidence at 9 months) is the primary end-point. Control angiography was performed only when clinically driven. Results: A total of 102 pts were included (mean age 66±11), (24 female), received a 54 SES and 48 a PAS. Demographic data were comparable with a proportion of 8 pts with unstable angina. Diabetes was present in 7 pts the SES group and in 6 pts in the PAS group. Baseline data and follow-up at 3 months are presented in the table below:The incidence of MACE did not differ after a mean follow-up of 3 ±4 months between the 2 groups. Particularly no pt died in either group. MI did not occur either. Only sub-acute thrombosis was documented in 2 pts in the PAS group. TLR and TVR were required in 0 pts in the SES group versus 2 pts in the PAS group. Conclusion: There was no significant difference in the incidence of MACE between sirolimus and paclitaxel group during this short follow-up. Nine-month follow-up will be available at time of presentation.
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Sirolimus Introduction: Antiproliferative strategies for the reduction of restenosis such as vascular brachytherapy (VBT) and drug-eluting Stents have proven to be safe and highly effective. While VBT is effective for the treatment of in-stent restenosis, the data for the treatment of de-novo lesions are less convincing. This study aimed to compare the safety and efficacy of VBT and Sirolimus-eluting Stents (Cypher) for the treatment of de-novo lesions. Methods: 53 individuals with de-novo lesions were treated with PTCA and Cypher-Stent Implantation. Matching was performed with the cohort of patients with de-novo lesions from the European RENO registry. This registry included the first 1098 patients treated with intracoronary beta-irradiation (Sr90) In-stent DS, % 5.0±6.7 3.3±8.0 7.7±13.5
In-stent late loss, mm 0.09±0.25 0.10±0.31 0.10±0.35
In-stent binary restenosis, % 0.0 0.0 3.6 (1)
